Zydus Lifesciences’ Verapamil Approval Analyzed
Zydus Lifesciences has successfully gotten the final stamp of approval from the United States Food and Drug Administration (USFDA) for a key medicine called Verapamil Hydrochloride Extended-Release Tablets. These tablets come in strengths of 120 mg, 180 mg, and 240 mg. They are used to treat high blood pressure, which is a major factor in preventing serious heart issues like strokes and heart attacks.
- Zydus got USFDA approval for Verapamil Hydrochloride tablets.
- Tablets treat high blood pressure effectively, reducing risks.
- 120mg, 180mg, and 240mg strengths available for patient needs.
- Production will occur at Zydus Lifesciences in Baddi, India.
- Sales reached $24.5 million in the US (September 2025 data).
- This approval strengthens Zydus’ position in the heart health market.
Production and Location
The Verapamil Hydrochloride Extended-Release Tablets will be manufactured at Zydus Lifesciences Ltd’s facility in Baddi, Himachal Pradesh, India. This localized production strengthens supply chains and responsiveness to market demand.
Sales Performance
Recent data from IQVIA shows that Verapamil Hydrochloride Extended-Release Tablets achieved an annual sales total of $24.5 million within the United States during the period of September 2025. This represents a significant market penetration for Zydus in this therapeutic area.
Effective medication development and strategic approvals are crucial for achieving market success.
